These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36153153)

  • 1. Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses.
    Dyson EH; Simpson AJH; Gwyther RJ; Cuthbertson H; Patient DH; Matheson M; Gregg A; Hepburn MJ; Hallis B; Williamson ED
    Vaccine; 2022 Oct; 40(42):6163-6178. PubMed ID: 36153153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
    Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
    Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the UK anthrax vaccine and human immunogenicity.
    Modi T; Gervais D; Smith S; Miller J; Subramaniam S; Thalassinos K; Shepherd A
    Hum Vaccin Immunother; 2021 Mar; 17(3):747-758. PubMed ID: 32897798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model.
    Kim GL; Pyo SW; Yi H; Kim SH; Shin H; Yu MA; Hwang YR; Choi SY; Jeon JH; Jo SK; Rhie GE
    Vaccine; 2023 May; 41(19):3106-3110. PubMed ID: 37055344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.
    Wright JG; Plikaytis BD; Rose CE; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Semenova VA; Li H; Schiffer J; Dababneh H; Martin SK; Martin SW; Marano N; Messonnier NE; Quinn CP
    Vaccine; 2014 Feb; 32(8):1019-28. PubMed ID: 24373307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
    Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults.
    Paolino KM; Regules JA; Moon JE; Ruck RC; Bennett JW; Remich SA; Mills KT; Lin L; Washington CN; Fornillos GA; Lindsey CY; O'Brien KA; Shi M; Mark Jones R; Green BJ; Tottey S; Chichester JA; Streatfield SJ; Yusibov V
    Vaccine; 2022 Mar; 40(12):1864-1871. PubMed ID: 35153091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax.
    Henning L; Anderson M; Triplett C; Smith T; Boyce K; Hendey L; Ridenour A; Eng J; Schaeufele D; Wilson E; Sabourin CL; Adams LE; Babas T; Parish L; Wolfe D
    Hum Vaccin Immunother; 2023 Dec; 19(3):2290345. PubMed ID: 38115181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.
    Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M
    Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
    Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
    Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques.
    Chen L; Schiffer JM; Dalton S; Sabourin CL; Niemuth NA; Plikaytis BD; Quinn CP
    Clin Vaccine Immunol; 2014 Nov; 21(11):1512-20. PubMed ID: 25185577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.
    Keitel WA; Treanor JJ; El Sahly HM; Evans TG; Kopper S; Whitlow V; Selinsky C; Kaslow DC; Rolland A; Smith LR; Lalor PA
    Hum Vaccin; 2009 Aug; 5(8):536-44. PubMed ID: 19458488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
    Taft SC; Weiss AA
    Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.
    Quinn CP; Sabourin CL; Schiffer JM; Niemuth NA; Semenova VA; Li H; Rudge TL; Brys AM; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Parker SD; Babcock J; Keitel W; Poland GA; Keyserling HL; El Sahly H; Jacobson RM; Marano N; Plikaytis BD; Wright JG
    Clin Vaccine Immunol; 2016 Apr; 23(4):326-38. PubMed ID: 26865594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.
    Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A
    Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.
    Little SF; Ivins BE; Webster WM; Fellows PF; Pitt ML; Norris SL; Andrews GP
    Vaccine; 2006 Mar; 24(14):2530-6. PubMed ID: 16417950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.
    Baillie LW; Huwar TB; Moore S; Mellado-Sanchez G; Rodriguez L; Neeson BN; Flick-Smith HC; Jenner DC; Atkins HS; Ingram RJ; Altmann DM; Nataro JP; Pasetti MF
    Vaccine; 2010 Sep; 28(41):6740-8. PubMed ID: 20691267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.